Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia

The antifungal efficacy, safety, and pharmacokinetics of posaconazole (SCH 56592) (POC) were investigated in treatment and prophylaxis of primary pulmonary aspergillosis due to Aspergillus fumigatus in persistently neutropenic rabbits. Antifungal therapy consisted of POC at 2, 6, and 20 mg/kg of bod...

Descrizione completa

Dettagli Bibliografici

Pubblicato in:	Antimicrob Agents Chemother
Autori principali:	Petraitiene, Ruta, Petraitis, Vidmantas, Groll, Andreas H., Sein, Tin, Piscitelli, Stephen, Candelario, Myrna, Field-Ridley, Aida, Avila, Nilo, Bacher, John, Walsh, Thomas J.
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society for Microbiology (ASM) 2001
Soggetti:	Experimental Therapeutics
Accesso online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90385/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11181372/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.45.3.857-869.2001
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!